SHPH
NASDAQ HealthcareShuttle Pharmaceuticals Holdings, Inc. - common stock
Drug Manufacturers - Specialty & Generic
Shuttle Pharmaceuticals Holdings, Inc., a clinical stage pharmaceutical company, develops novel therapies to cure cancers. The company is developing Ropidoxuridine, an oral halogenated pyrimidine to treat patients with brain tumors and sarcomas; and SP-2-225, a pre-clinical class IIb product candidate that effects on the regulation of the immune system. It is also developing SP-1-303, a pre-clinical selective Class I HDAC for use in the treatment of ER positive breast cancers; and SP-1-161, a HDAC inhibitor that initiates the mutated in ataxia-telangiectasia response pathway. The company was founded in 2012 and is headquartered in Gaithersburg, Maryland.
๐ Market Data
| Price | $0.69 |
|---|---|
| Volume | 18,172,361 |
| Market Cap | 3.87M |
| Beta | 0.720 |
| RSI (14-Day) | 47.8 |
| 200-Day MA | $2.30 |
| 50-Day MA | $0.90 |
| 52-Week High | $11.25 |
| 52-Week Low | $0.50 |
| Price / Book | 0.61 |
๐ฏ Investment Strategy Scores
SHPH scores across each investment strategy. Higher is better for that strategy's goals.
๐ Strategy Interpretation
Best fit: ๐ช Falling Knife (99/100) โ this strategy Contrarian plays (oversold + below moving average).
Lowest fit among scored strategies: ๐ Over-Hyped (30/100). No single score is a buy or sell signal โ use multiple lenses together. Learn how to read these scores โ
๐ Learn More
Indicators on this page
Educational articles
Find SHPH in your text
Paste any article, transcript, or post โ the tool will extract SHPH and every other hidden ticker.
Disclaimer: This data is for educational and entertainment purposes only and does not constitute financial advice. Market data may be delayed. Always do your own research before making investment decisions.
Data last updated: 2026-05-01.